emka TECHNOLOGIES S.A.S

Emka Biotech, based in France, specializes in developing advanced hardware solutions for preclinical physiological monitoring, facilitating research in cardiology, toxicology, and neuroscience. Emka Biotech, established in 1991 in Paris, France, focuses on creating innovative monitoring solutions for preclinical research. The company has undergone a significant acquisition, with Fonds de Solidarité des Travailleurs du Québec and investor David Brunet acquiring emka TECHNOLOGIES S. A.

S on August 2, 2021. The total amount raised by the company to date is EUR 1. 00 mn, with the most recent funding round also amounting to EUR 1. 00 mn, supported by investor Siparex.

Emka Biotech has completed 2 deals in total. emka TECHNOLOGIES offers specialized preclinical physiological monitoring solutions, including easyTEL+, a digital telemetry system for transmitting physiological data, ecgTUNNEL for non-invasive ECG and respiration data recording, and ecgAUTO software for advanced cardiovascular analysis. These products cater to academic institutions, biomedical research organizations, and pharmaceutical companies primarily in North America and Europe, enhancing the accuracy and efficiency of preclinical research. emka TECHNOLOGIES generates revenue through direct B2B sales of its products and services, focusing on research institutions and laboratories.

Their model incorporates individual product sales, such as easyTEL+ and ecgAUTO, along with service agreements for installation and support, ensuring a steady income stream while facilitating high-quality preclinical research. Following the acquisition in August 2021, Emka Biotech aims to expand its scientific research operations into broader medical fields. Future initiatives include the design and launch of new products to enhance their offerings in physiological monitoring. Funding from the recent acquisition will support these expansions and the development of innovative solutions tailored for emerging market needs.